Do Dose-Dense Neoadjuvant Chemo Regimens Improve Responses in Bladder Cancer?
A dose-dense neoadjuvant chemotherapy regimen yielded higher response rates compared with a standard regimen in a cohort of bladder cancer patients. (Source: CancerNetwork)
Source: CancerNetwork - September 19, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Timing of DWI-MRI predicts breast cancer response
Diffusion-weighted MR images acquired 12 weeks after the start of neoadjuvant...Read more on AuntMinnie.comRelated Reading: Breast cancer follow-up imaging varies widely Breast MRI underutilized in high-risk women Multiparametric MRI shines for suspected breast cancer Is screening breast MRI being used in the wrong women? Breast MRI technique helps cancer detection without contrast (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 11, 2018 Category: Radiology Source Type: news

Which Is Best Neoadjuvant Chemo in Bladder Cancer? Which Is Best Neoadjuvant Chemo in Bladder Cancer?
A nonstandard neoadjuvant chemotherapy was associated with higher complete response rates and more downstaging in patients with muscle-invasive bladder cancer.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 10, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Mayo Clinic physicians receive Stand up to Cancer Catalyst Award for melanoma research
This study, ?Neoactivate?, will test two novel approaches to the treatment of patients with high-risk, stage 3 melanoma guided by specific mutations within [...] (Source: Mayo Clinic Minnesota News)
Source: Mayo Clinic Minnesota News - September 6, 2018 Category: Hospital Management Source Type: news

' Compelling' Regimen for Resectable Advanced-Stage Melanoma'Compelling' Regimen for Resectable Advanced-Stage Melanoma
Dr Weber reviews a new trial comparing neoadjuvant and adjuvant dual MEK/BRAF inhibition to standard of care in advanced resectable melanoma.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 16, 2018 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

Neoadjuvant Score as Surrogate for DFS in Rectal Cancer Neoadjuvant Score as Surrogate for DFS in Rectal Cancer
A score incorporating categories for disease-free survival can help clinicians make faster decisions about treatment for rectal cancer.Annals of Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 16, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Improving Surgery for Mesothelioma with Glowing Tumor Technology
Thoracic surgeon Dr. Sunil Singhal at the Abramson Cancer Center has developed glowing tumor technology that should increase the effectiveness of aggressive surgery for malignant pleural mesothelioma. Singhal has shown recently that by adding a contrast agent that makes tumor cells glow, a more complete surgery can be done. This potentially avoids the now almost-inevitable cancer recurrence. “This is a big deal. We could potentially help a lot of patients with this,” Singhal told Asbestos.com. “It could change the entire field [of surgery for mesothelioma].” Singhal and his colleagues from the Abram...
Source: Asbestos and Mesothelioma News - August 9, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

New RCT Favors Standard of Care for Squamous Cervical Cancer New RCT Favors Standard of Care for Squamous Cervical Cancer
Neoadjuvant chemotherapy falls short of chemoradiation in this new study.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 30, 2018 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Implications of CTCs in Early Breast Cancer Implications of CTCs in Early Breast Cancer
Can CTCs be used to predict prognosis and response to neoadjuvant chemotherapy in nonmetastatic breast cancer?Journal of the National Cancer Institute (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 20, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Higher OS With Neoadjuvant Chemo-RT in Pancreatic Cancer
In PREOPANC, the 2-year survival rate was significantly higher for patients who received neoadjuvant chemoradiotherapy vs standard care. (Source: CancerNetwork)
Source: CancerNetwork - June 20, 2018 Category: Cancer & Oncology Authors: Cancer Network Editors Source Type: news

Chemoradiation Prevails in Cervical Cancer Trial
(MedPage Today) -- Reduced disease-free survival with neoadjuvant chemotherapy plus surgery (Source: MedPage Today OB/GYN)
Source: MedPage Today OB/GYN - June 15, 2018 Category: OBGYN Source Type: news

A 35-Year-Old Woman With a Change in HER2 Expression Following Neoadjuvant Chemotherapy for Invasive Breast Cancer
A 35-year-old woman noticed a mass in her right breast and underwent a diagnostic workup, including a mammogram that revealed a 2.4-cm mass and ultrasound that showed two adjacent masses, as well as enlarged axillary lymph nodes. (Source: CancerNetwork)
Source: CancerNetwork - June 15, 2018 Category: Cancer & Oncology Authors: Ericson Stoen, MD, Peter Kabos, MD, Kelly C. Borden, MD, Regina J. Brown, MD, Virginia F. Borges, MD, MMSc, Jennifer R. Diamond, MD Source Type: news

Race May Be Factor in Completion of Neoadjuvant Breast CA Chemo Race May Be Factor in Completion of Neoadjuvant Breast CA Chemo
White women with breast cancer are more likely to complete their neoadjuvant chemotherapy regimen than women of color, a U.S. study suggests.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 14, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Neoadjuvant CRT May Improve Survival in Pancreatic Cancer Neoadjuvant CRT May Improve Survival in Pancreatic Cancer
Results are preliminary, but patients who received neoadjuvant chemoradiation had better outcomes than did those who had immediate surgery.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 8, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Noninferiority of Neoadjuvant Chemo Cannot Be Confirmed in Ovarian Cancer Trial
Dave LevitanJun 6, 2018The noninferiority of neoadjuvant chemotherapy vs upfront surgery could not be confirmed with regard to overall survival in patients with ovarian, tubal, and peritoneal cancers. (Source: CancerNetwork)
Source: CancerNetwork - June 6, 2018 Category: Cancer & Oncology Authors: A Source Type: news

First study of neoadjuvant use of PARP inhibitor shows promise for early-stage, BRCA+ breast cancer patients
(University of Texas M. D. Anderson Cancer Center) In a small Phase II study of early-stage breast cancer patients with BRCA1/2 mutations, researchers at The University of Texas MD Anderson Cancer Center found that more than half of the women who took the PARP inhibitor talazoparib once daily prior to surgery had no evidence of disease at the time of surgery. If further validated in larger, confirmatory trials, the oral medication could replace chemotherapy for these patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 4, 2018 Category: Cancer & Oncology Source Type: news

Dose-Dense Chemo Shows Promise as Neoadjuvant Therapy in Bladder Cancer
A neoadjuvant dose-dense regimen was active and well tolerated in patients with muscle-invasive bladder cancer, allowing downstaging of most patients before radical cystectomy. (Source: CancerNetwork)
Source: CancerNetwork - May 11, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Bladder Cancer Genitourinary Cancers SiteTerms/www.cannabissciencetech.com/News Source Type: news

Nodal Response to Pre-Op Tx Tied to Survival in Esophageal Cancer
WEDNESDAY, May 2, 2018 -- For patients with locally advanced esophageal cancer, the status of lymph nodes following preoperative neoadjuvant chemotherapy or chemoradiation therapy determines survival, according to a study presented at the annual... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 2, 2018 Category: Pharmaceuticals Source Type: news

For patients with esophageal cancer, status of lymph nodes after preoperative therapy determines survival
(American Association for Thoracic Surgery) The status of lymph nodes rather than the status of the primary tumor following preoperative neoadjuvant chemotherapy or chemoradiation therapy is the most important factor that determines whether patients with locally advanced esophageal cancer will survive. The study presented at the AATS 98th Annual Meeting indicates that while preoperative chemotherapy and radiation therapy improve survival of patients with esophageal cancer, patients with malignant lymph nodes following therapy were less likely to survive than patients with no cancer in the lymph nodes. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 1, 2018 Category: Cancer & Oncology Source Type: news

Improved Rectal-Cancer Survival Seen With Adjuvant Chemotherapy Improved Rectal-Cancer Survival Seen With Adjuvant Chemotherapy
Adjuvant chemotherapy is associated with improved overall survival in patients with rectal cancer and pathological complete response after neoadjuvant chemotherapy and resection.Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 27, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Neoadjuvant Immunotherapy Data Suggest More Lung Cancer Cures Neoadjuvant Immunotherapy Data Suggest More Lung Cancer Cures
Among the new data on immunotherapy for lung cancer presented at the recent AACR meeting, the potential role of immune checkpoint inhibitors in the neoadjuvant setting may be the most promising.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 26, 2018 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Neoadjuvant Nivolumab Yields High Response in Newly Diagnosed NSCLC
Neoadjuvant nivolumab combo proved safe while yielding high response rates in patients with NSCLC. (Source: CancerNetwork)
Source: CancerNetwork - April 25, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Lung Cancer News Source Type: news

Circulating Tumor Cell Count Predicts Early Breast Cancer Outcomes Circulating Tumor Cell Count Predicts Early Breast Cancer Outcomes
Circulating tumor cell (CTC) count independently predicts outcomes in women with early breast cancer treated with neoadjuvant chemotherapy, according to a meta-analysis.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - April 24, 2018 Category: Pathology Tags: Hematology-Oncology News Source Type: news

Improved Pancreatic Survival Seen After Neoadjuvant Therapy and Surgery Improved Pancreatic Survival Seen After Neoadjuvant Therapy and Surgery
Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 19, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Neoadjuvant Anti-PD-1 Active in Multiple Tumors (CME/CE)
(MedPage Today) -- Major responses in pilot study for NSCLC, melanoma, bladder cancers (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - April 18, 2018 Category: Dermatology Source Type: news

Neoadjuvant Nivolumab Shows Benefit in NSCLC Neoadjuvant Nivolumab Shows Benefit in NSCLC
Already used for nonresectable lung cancer, immunotherapy is now heading for the neoadjuvant niche, with nivolumab showing benefit when used before surgery.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 17, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

TNT Is Viable for Locally Advanced Rectal Cancer
CR was 36% in the total neoadjuvant therapy cohort vs 21% in the cohort that received chemoradiotherapy with adjuvant chemotherapy. (Source: CancerNetwork)
Source: CancerNetwork - April 6, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Colorectal Cancer News Source Type: news

Total Neoadjuvant Approach Promising in Locally Advanced Rectal Cancer Total Neoadjuvant Approach Promising in Locally Advanced Rectal Cancer
Preoperative chemotherapy in combination with chemoradiation (total neoadjuvant therapy, or TNT) appears to have advantages over traditional approaches to treating locally advanced rectal cancer, according to new research.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - April 3, 2018 Category: Surgery Tags: Hematology-Oncology News Source Type: news

Some HER2+ Breast Cancer Patients Could Avoid SLNB Following Neoadjuvant Therapy
Two new studies have found that some HER2-positive and triple-negative breast cancer patients can avoid sentinel lymph node biopsy after neoadjuvant systemic therapy. (Source: CancerNetwork)
Source: CancerNetwork - April 2, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer HER2-Positive Breast Cancer News Triple-Negative Breast Cancer Source Type: news

Carboplatin in Neoadjuvant Chemo May Be Helpful in Triple-negative Breast Cancer Carboplatin in Neoadjuvant Chemo May Be Helpful in Triple-negative Breast Cancer
Carboplatin should be considered as a potential component of neoadjuvant chemotherapy for women with high-risk, triple-negative breast cancer, regardless of BRCA status, researchers suggest.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 19, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Biomarkers to Predict Treatment Response in Bladder Cancer Biomarkers to Predict Treatment Response in Bladder Cancer
A new study looks at whether certain biomarkers may predict response to adjuvant and neoadjuvant treatments for bladder cancer.Translational Andrology and Urology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 28, 2018 Category: Consumer Health News Tags: Urology Journal Article Source Type: news

Neoadjuvant Therapy Controls High-Risk Melanoma (CME/CE)
(MedPage Today) -- Trial of targeted combination stopped early (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - January 30, 2018 Category: Dermatology Source Type: news

More Intense Neoadjuvant ECX Regimen Fails for Esophageal Cancer More Intense Neoadjuvant ECX Regimen Fails for Esophageal Cancer
Dr Kerr reports on a large, well-designed trial with disappointing results.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 25, 2018 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Rethinking neoadjuvant chemotherapy for breast cancer
This BMJ analysis notes that neoadjuvant chemotherapy may not be beneficial to patients as increased pathological response of primary tumour does not translate into a survival benefit. It suggests that the widespread use of neoadjuvant chemotherapy should be reduced. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - January 12, 2018 Category: Consumer Health News Source Type: news

Neoadjuvant Chemotherapy Tied to Better Survival in Advanced Ovarian Cancer Neoadjuvant Chemotherapy Tied to Better Survival in Advanced Ovarian Cancer
The adoption of neoadjuvant chemotherapy is associated with reduced mortality in women with advanced epithelial ovarian cancer, researchers report.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 10, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Neoadjuvant Chemotherapy Tied to Improved Ovarian Cancer Survival
In women with advanced ovarian cancer, increased use of neoadjuvant chemotherapy (NACT) followed by surgery — rather than primary cytoreductive surgery — is associated with reduced mortality... (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - January 5, 2018 Category: Primary Care Source Type: news

Adjuvant and Neoadjuvant Therapy for Pancreatic Cancer Adjuvant and Neoadjuvant Therapy for Pancreatic Cancer
Ongoing clinical trials are evaluating aggressive chemotherapy regimens and radiotherapy in pancreatic cancer.Chinese Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 2, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Neoadjuvant Radiotherapy of Early-Stage Breast Cancer Neoadjuvant Radiotherapy of Early-Stage Breast Cancer
Does neoadjuvant radiotherapy improve overall survival in women with early-stage breast cancer?Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 22, 2017 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Why Is Neoadjuvant Endocrine Therapy Underused in Breast Cancer? Why Is Neoadjuvant Endocrine Therapy Underused in Breast Cancer?
Experts discuss the evidence behind neoadjuvant endocrine therapy for early-stage breast cancer and obstacles to wider use of this treatment strategy.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 20, 2017 Category: Consumer Health News Tags: Hematology-Oncology Article Source Type: news

Contrast-enhanced digital mammography comparable to breast MRI after therapy or chemo
(Mayo Clinic) Contrast-enhanced digital mammography is comparable to breast MRI in evaluating residual breast cancer after neoadjuvant endocrine therapy or chemotherapy, according to the results of a study presented by Mayo Clinic researchers today at the 2017 San Antonio Breast Cancer Symposium. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 6, 2017 Category: Cancer & Oncology Source Type: news

FDA accepts regulatory submission for Lynparza in metastatic breast cancer and grants Priority Review
AstraZeneca and Merck & Co., Inc., (Merck: known as MSD outside the US and Canada) today announced that the US Food and Drug Administration (FDA) has accepted and granted Priority Review for a supplemental New Drug Application (sNDA) for the use of Lynparza (olaparib) tablets in patients with germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer who have been previously treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic settings. (Source: World Pharma News)
Source: World Pharma News - October 18, 2017 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

Chemoradiotherapy Remains Standard of Care in Cervical Cancer Chemoradiotherapy Remains Standard of Care in Cervical Cancer
Chemoradiotherapy remains the standard of care for cervical cancer patients with locally advanced disease, concludes an Indian trial that compared it to neoadjuvant chemotherapy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 11, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Amgen And Allergan Present Phase 3 Data On Biosimilar Trastuzumab Candidate ABP 980 At The European Society For Medical Oncology 2017 Congress
Study Between ABP 980 and Trastuzumab in Patients With HER2-Positive Early Breast Cancer Adds to the Totality of Evidence of Biosimilarity THOUSAND OAKS, Calif. and DUBLIN, Sept. 9, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced data from a Phase 3 study evaluating the efficacy and safety of ABP 980, a Herceptin® (trastuzumab) biosimilar, compared with the originator product in patients with human epidermal growth factor receptor 2-positive (HER2-positive) early breast cancer. Results from the neoadjuvant efficacy phase of the study, including pathologic complete response ass...
Source: Amgen News Release - September 9, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Study confirms chemoradiation is best treatment for locally advanced cervical cancer
(European Society for Medical Oncology) A 14-year randomized trial in more than 600 patients has concluded that chemoradiation should remain the standard treatment for patients with locally advanced cervical cancer. The findings are reported today at the ESMO 2017 Congress in Madrid. The trial demonstrated no improved disease-free survival with neoadjuvant chemotherapy followed by surgery. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 9, 2017 Category: Cancer & Oncology Source Type: news

CT Abnormality in Patient With Stage II Breast Cancer History
A 57-year-old woman with a history of stage IIB breast cancer (ypT2N1M0) status post neoadjuvant chemotherapy and left partial mastectomy presents to the radiation oncology clinic for CT simulation in preparation for breast radiotherapy. Noncontrast CT scan incidentally found the abnormality depicted with arrows below. (Source: CancerNetwork)
Source: CancerNetwork - September 8, 2017 Category: Cancer & Oncology Authors: Joseph Miccio, MD Tags: Image IQ Source Type: news

Cynvenio and Saint Luke ’s Cancer Institute Launch Pilot Study to...
New Study will use LiquidBiopsy® ClearID® testing and NK Score™ natural killer cell activity testing to monitor breast cancer patients following neoadjuvant chemotherapy.(PRWeb August 17, 2017)Read the full story at http://www.prweb.com/releases/2017/08/prweb14601181.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - August 17, 2017 Category: Pharmaceuticals Source Type: news

Urothelial Cancer Response to Neoadjuvant Chemo Varies by Histologic Variant
Certain histologic variants of urothelial bladder cancer benefit more from neoadjuvant chemotherapy, according to a new study. (Source: CancerNetwork)
Source: CancerNetwork - August 3, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Bladder Cancer Genitourinary Cancers News Source Type: news

Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
This research article has led to a Practice Changing Update on DynaMed Plus. It concludes that capecitabine adjuvant therapy may improve survival in women with HER2-negative residual invasive breast cancer after neoadjuvant chemotherapy (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - July 19, 2017 Category: Consumer Health News Source Type: news

Radiation prior to surgery reduces risk of secondary tumors in early-stage breast cancer
(H. Lee Moffitt Cancer Center& Research Institute) Moffitt researchers found that patients who have neoadjuvant radiation therapy have a significantly lower risk of developing a second primary tumor at any site. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 17, 2017 Category: Cancer & Oncology Source Type: news

T-DM1 Promising as Neoadjuvant Therapy in Early BC (CME/CE)
(MedPage Today) -- 41% of HER2+/HR+ patients achieved a pathologic complete response (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - July 16, 2017 Category: Hematology Source Type: news